What Happened

TScan Therapeutics presented initial data from Cohort C of its ALLOHA Phase 1 study, showing 11 of 14 patients achieved complete donor chimerism within ~3 weeks of first TSC-101 infusion. The commercial-ready manufacturing process demonstrated consistency, supporting the planned Phase 3 trial initiation this month.

Who Is Affected

Hematologic malignancy patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) are the primary treatment population. Oncologists, transplant specialists, and hospital procurement teams at cancer centers should track this development.

Market Impact

• Advances TCR-T therapy pipeline for post-transplant relapse prevention
• Validates commercial manufacturing process ahead of Phase 3
• 93% response rate in higher-risk population strengthens clinical case

What to Watch

Monitor Phase 3 ALLOHA-2 enrollment starting this month. The June 22 KOL event with Dr. Ran Reshef provides additional clinical insights. Follow-on product candidates in heme and solid tumors represent pipeline expansion opportunities.